REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K

What Happened
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) filed a Current Report on Form 8-K on April 15, 2026 to disclose a letter to shareholders announcing business updates. The letter describes the company’s program for development of brilaroxazine for the treatment of schizophrenia and outlines the company’s intellectual property strategy; the shareholder letter is furnished as Exhibit 99.1 to the filing. The disclosure was made under Regulation FD (Item 7.01) and is also noted under Other Events (Item 8.01).

Key Details

• Filing date: April 15, 2026 (Form 8-K).
• Program: Brilaroxazine development program for the treatment of schizophrenia is highlighted in the shareholder letter.
• Corporate action: The company issued a letter to shareholders detailing business updates and its intellectual property strategy; the letter is Exhibit 99.1 to the 8-K.
• Reported items: Disclosure recorded under Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other Events).

Why It Matters
This filing informs investors that Reviva is publicly communicating progress and strategy for its lead candidate, brilaroxazine, and clarifying its approach to intellectual property — both items that can affect the company’s development timeline and competitive positioning. The 8-K does not announce clinical results, financial figures, or management changes; investors focused on drug development, patents, or upcoming milestone news should review the attached shareholder letter (Exhibit 99.1) for details.